First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial

© 2016 Eli Lilly and Company. Background The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advan...

Full description

Saved in:
Bibliographic Details
Main Authors: Mark Boye, Xin Wang, Vichien Srimuninnimit, Jin Hyoung Kang, Chun Ming Tsai, Mauro Orlando, Tarun Puri, Jong Seok Kim, Narayan Rajan, James Chih Hsin Yang
Other Authors: Eli Lilly and Company
Format: Article
Published: 2018
Subjects:
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/43091
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University
Be the first to leave a comment!
You must be logged in first